Inhalation anesthetics (such as nitrous oxide, halothane, isoflurane, desflurane, and sevoflurane; most commonly used agents in practice today) are used for induction and maintenance of general anesthesia in the operating room. Inhaled anesthetics are preferred for maintenance of anesthesia because they allow a more precise control of the anesthetic state and do so at low cost.

Market Dynamics:

Increasing prevalence of chronic disease, growing geriatric (aging) population, increasing number of emergency cases and surgical interventions, increase in demand for inhalation anesthesia, and outbreak of COVID-19 (pandemic) are major factors expected to augment the growth of the global inhalation anesthesia market during the forecast period.

For instance, in August 2022, Piramal Pharma Limited's Critical Care business, a leading Complex Hospital Generics company, announced the First to Market Generic U.S. launch of the Zinc Sulfate Injection. This product is U.S. Food and Drug Administration approved with Competitive Generic Therapy (CGT) designation; an approval pathway intended to enhance market competition for sole source drugs. The injection is available in 30mg/10mL (3mg/mL) and 25mg/5mL (5mg/mL).

Key features of the study:

• This report provides in-depth analysis of the global inhalation anesthesia market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2020 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global inhalation anesthesia market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Abbvie Inc., Novartis AG, Piramal Enterprises Ltd., Hikma Pharmaceuticals Plc, Fresenius SE & CO. KGaA, Halocarbon Products Corporation, Baxter International Inc., Troikaa Pharmaceuticals, Ltd., Jiangsu Hengrui Medicine Co., Ltd., Lunan Pharmaceutical Group Co. Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global inhalation anesthesia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalation anesthesia market.

Detailed Segmentation:

• Global Inhalation Anesthesia Market, By Product:
  • Sevoflurane
  • Desflurane
  • Isoflurane
  • Nitrous Oxide
• Global Inhalation Anesthesia Market, By Application:
  • Induction
  • Maintenance
• Global Inhalation Anesthesia Market, By End User:
  • Hospitals
  • Ambulatory Surgical Centers
• Global Inhalation Anesthesia Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Abbvie Inc.
  • Novartis AG
  • Piramal Enterprises Ltd.
  • Hikma Pharmaceuticals Plc
  • Fresenius SE & CO. KgaA
  • Baxter International Inc.
  • Troikaa Pharmaceuticals, Ltd.
  • Halocarbon Products Corporation
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lunan Pharmaceutical Group Co. Ltd.